Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBLearning to live with both sleep apnea and pulmonary fibrosis. Living with pulmonary fibrosis is already a daunting challenge, but when coupled with a sleep disorder like sleep apnea, the burden becomes even heavier. Sleep apnea, a condition in which breathing repeatedly stops and starts during sleep, can significantly impact both sleep quality ...
The need for pulmonary fibrosis awareness never ends
WEB1 day ago · The need to continue raising pulmonary fibrosis awareness is real. Next month I’ll be taking part in the Pulmonary Fibrosis Foundation Walk in National Harbor, Maryland, where the goal is to “walk together toward a cure for pulmonary fibrosis.”. If you’re in the area, come introduce yourself and join my team, Fibrosis Fighters, in October.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. $15K award goes to researcher for work into IPF disease risk factors September 20, 2024; Learning to live with both sleep apnea and pulmonary fibrosis September 17, 2024; Navigating emotional ups and downs on my IPF journey September 17, 2024; Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF September 13, 2024; A new twist in my journey: Familial idiopathic ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
WEBApr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
Top 10 Pulmonary Fibrosis Stories of 2021
WEBJan 3, 2022 · breathing exercises, Collagen turnover, esopremazole, MDM4, N115, pterostilbene, renin-angiotensin system, Salvianolic acid B, Top 10, TXR-1002, TXR-1007, Tyvaso, vitamin D. Pulmonary Fibrosis News counts down its top 10 most-read stories of 2021, noting what made each relevant for the PF community.
Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF...
WEBAug 30, 2022 · Saracatinib worked as well or better than Ofev or Esbriet at reducing tissue scarring, or fibrosis, in cell and animal models of IPF, a study showed.. The oral therapy was identified as an IPF treatment candidate based on a computational approach that analyzed the potential anti-fibrotic effects of several medications developed for …
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
WEBAug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, and conditions such as chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH) can impact disease prognosis.
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...